Search the web
Welcome, Guest
[Sign Out, My Account]

Saturday, March 28 2015 12:25am ET - U.S. Markets Closed.
Industry Center - Drug Manufacturers - Major
Industry Center > Drug Manufacturers - Major > Reliant Pharmaceuticals, Inc. Company Profile
More On This Industry
· Summary
· News
· Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
· REIT - Retail
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Need more? Get unbiased, in-depth information on public and private companies worldwide.
Reliant Pharmaceuticals, Inc. Company Profile
Reliant Pharmaceuticals gets to the heart of the matter. The company markets controlled-release treatments for various cardiovascular ailments. Rather than go through the time and expense of developing drugs from start to finish in its own labs, the drugmaker instead buys rights to already-approved or late-stage development pharmaceuticals. Reliant's portfolio of cardiovascular drugs includes omega-3 product Lovaza, which combats high triglycerides (fatty substances that may cause coronary heart disease); high blood-pressure meds InnoPran XL and DynaCirc; and irregular heart-rhythm treatment Rhythmol SR. Reliant Pharmaceuticals was acquired by GlaxoSmithKline (GSK) for $1.65 billion in 2007.
Headlines for Reliant Pharmaceuticals, Inc.
Sigma annual profit flat
- Wed Mar 18
Sigma focusing on improving pharmacies
- Wed Mar 18
Pfizer hunts for new vaccines to protect young and old
- Thu Mar 12
Copy me: Europe shows U.S. a path to cheaper biotech drugs
- Fri Mar 6
Contact Information
Address: 110 Allen Rd.
Liberty Corner, NJ 07938
Financial Highlights
Fiscal Year End:December
Revenue (2006):367.50 M
Revenue Growth (1 yr):67.30%
Employees (2006):1,000
Key People
Chairman: Frederick B. (Fred) Craves
CFO: Robert R. (Bob) Ferguson III
SVP Sales and Marketing: Vincent J. Angotti
Industry Information
Sector: Healthcare
Industry: Drug Manufacturers - Major
Top Competitors
AstraZeneca PLC (azn)
Bristol-Myers Squibb Company (bmy)
Pfizer Inc. (pfe)

Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2015 Morningstar, Inc. All Rights Reserved. Company information © 2015 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2015, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?